SURAMIN ACTIVIY IN HUMAN HEAD AND NECK SQUAMOUS CELL CARCINOMA——Ⅱ.EFFECT OF SURAMIN ON HUMAN HEAD AND NECK CARCINOMA XENOGRAFTS AND RELATED TOXICITY AND PHARMACOKINETIC STUDIES IN NUDE MICE

In part Ⅰ of the study,we have demonstrated that suraminhas a marked antiproliferative effect on human head and neck squamous cellcarcinoma cell lines,In the present study,both toxicity and pharmacokineticstudies in nude mice were done.The treatment of nude mice bearing head andneck cancers with suramin showed that suramin had a minimal antitumor effect.The possible mechanism of suramin lacking antitumor effect is discussed.     

Combined surgery and radiation therapy for squamous cell carcinoma of the hypopharynx

Squamous cell carcinoma of the hypopharynx remains a highly lethal disease. This article documents our experience with 132 patients undergoing surgical management of squamous cell carcinoma of the hypopharynx, of whom 80% received postoperative radiation therapy. Local-regional control was obtained in 61% of the patients. Five-year overall and disease-free survival rates were 30% and 41%, respectively. Prognosis was better in patients with limited disease: local disease permitting larynx-sparing surgery, N0/N1 clinical neck, and stage I/II/III disease. Cancer of the hypopharynx remains an aggressive entity associated with poor prognosis. Novel strategies stressing improved local-regional control with prevention of distant metastasis are warranted. (Otolaryngol Head Neck Surg 1997; 116: 637-41.)     

Annexin A1 subcellular expression in laryngeal squamous cell carcinoma

Aims: Annexin A1 (ANXA1) is a soluble cytoplasmic protein, moving to membranes when calcium levels are elevated. ANXA1 has also been shown to move to the nucleus or outside the cells, depending on tyrosine‐kinase signalling, thus interfering in cytoskeletal organization and cell differentiation, mostly in inflammatory and neoplastic processes. The aim was to investigate subcellular patterns of immunohistochemical expression of ANXA1 in neoplastic and non‐neoplastic samples from patients with laryngeal squamous cell carcinomas (LSCC), to elucidate the role of ANXA1 in laryngeal carcinogenesis. Methods and results: Serial analysis of gene expression experiments detected reduced expression of ANXA1 gene in LSCC compared with the corresponding non‐neoplastic margins. Quantitative polymerase chain reaction confirmed ANXA1 low expression in 15 LSCC and eight matched normal samples. Thus, we investigated subcellular patterns of immunohistochemical expression of ANXA1 in 241 paraffin‐embedded samples from 95 patients with LSCC. The results showed ANXA1 down‐regulation in dysplastic, tumourous and metastatic lesions and provided evidence for the progressive migration of ANXA1 from the nucleus towards the membrane during laryngeal tumorigenesis. Conclusions: ANXA1 dysregulation was observed early in laryngeal carcinogenesis, in intra‐epithelial neoplasms; it was not found related to prognostic parameters, such as nodal metastases.     

The role of the IGF axis in IGFBP-1 and IGF-I induced renal enlargement in Snell dwarf mice

Insulin-like growth factor (IGF) binding protein-1 (IGFBP-1) is generally believed to inhibit IGF action in the circulation. In contrast, IGFBP-1 has been reported to interact with cell surfaces and enhance IGF-I action locally in some tissues. Renal IGFBP-1 levels are found elevated in various conditions characterized by renal growth (e.g. diabetes mellitus, hypokalemia). To test whether IGFBP-1 is a renotropic factor, IGFBP-1 was administered alone or in combination with IGF-I to Snell dwarf mice, an in vivo model without compensatory feedback effects on growth hormone (GH) secretion. In three control groups of Snell dwarf mice, placebo, GH or IGF-I was administered. Compared with placebo, kidney weight increased in all treated groups, however, with different effects on kidney morphology. Administration of IGF-I, alone or in combination with IGFBP-1, tended to increase glomerular volume, while no changes were seen in the other groups. Administration of IGFBP-1 or IGFBP-1+IGF-I both caused dilatation of the thin limbs of Henle's loop, while GH or IGF-I administration had no visible effect. Furthermore, IGF-I administration resulted in an increased mean number of nuclei per cortical area and renal weight, whereas GH, IGF-I+IGFBP-1 or IGFBP-1 caused a decreased renal nuclei number. In situ hybridization and immunohistochemistry showed specific changes of the renal IGF system expression patterns in the different groups. Particularly, IGFBP-1 administration resulted in extensive changes in the mRNA expression of the renal IGF system, whereas the other administration regimen resulted in less prominent modifications. In contrast, administration of IGFBP-1 and IGFBP-1+IGF-I resulted in identical changes in the protein expression of the renal IGF system. Our results indicate that IGFBP-1, alone or in combination with IGF-I, demonstrated effects on the renal tubular system that differ from the effects of IGF-I.     

Ueber „Stauungsblutungen nach Rumpfcompression”

Ohne Zusammenfassung     

不同术前放射治疗剂量在下咽鳞癌综合治疗中的意义

目的　探讨下咽鳞癌不同术前放射治疗剂量对综合治疗的影响。方法　回顾性分析2 0 1例 (男 181例 ,女 2 0例 ;年龄 32～ 75岁 )经术前放射治疗 手术综合治疗 (R S)的下咽鳞癌 (1997年UICC分期Ⅰ期 6例 ,Ⅱ期 14例 ,Ⅲ期 4 7例 ,Ⅳ期 134例 ) ,其中梨状窝 173例 ,咽后壁 19例 ,环后 9例。 12 4例术前放射治疗 4 0Gy ,77例术前放射治疗 5 0Gy ;放射治疗后 2周左右给予手术治疗。结果　术前放射治疗 4 0Gy组 5年生存率为 39.7% ,5 0Gy组为 5 5 .4 % (P <0 .0 5 )。术前放射治疗 4 0Gy组放射治疗相关性术后并发症发生率为 2 6 .6 % ,5 0Gy组为 15 .6 % (P <0 .0 5 )。术前放射治疗 4 0Gy组喉功能保留率为 38.7% ,5 0Gy组为 4 2 .9% (P >0 .0 5 )。术前放射治疗 4 0Gy组区域复发率为 2 8.2 % ,5 0Gy组为 2 9.9% (P >0 .0 5 )。结论　术前放射治疗 5 0Gy较 4 0Gy能提高下咽鳞癌的远期生存率 ,且不增加放射治疗引起的术后并发症 ,并有望增加喉功能的保留率。